CDC study shows deaths from vaccine-preventable diseases at all-time low in U.S.
WASHINGTON The frequency of vaccine-preventable deaths has reached an all-time low in the United States, according to a new federal report.
The study, by researchers at the U.S. Centers for Disease Control and Prevention, revealed that childhood vaccinations have reduced the death rates from seven previously common childhood illnesses, such as diphtheria, mumps and measles, by 100 percent. “The number of cases of most vaccine-preventable diseases is at an all-time low; hospitalizations and deaths have also shown striking decreases,” wrote the authors of the study, which is published in the Nov. 14 issue of the Journal of the American Medical Association.
The study compared the number of cases and deaths for 13 vaccine-preventable deaths, including tetanus, polio and smallpox. The researchers compared the most recent data on illnesses (from 2006) and deaths (from 2004) to pre-vaccination rates.
For immunizations developed prior to 1980, there was a 92 percent reduction in vaccine-preventable illnesses and a 99 percent or greater decline in deaths due to vaccine-preventable diseases.
Vaccines that were introduced after 1980, including the hepatitis vaccines and chickenpox, there was an 80 percent or greater decline in illness and deaths. Cases of invasive pneumococcal disease were down 34 percent, and death rates were down 25 percent.
“These achievements are largely due to reaching and maintaining high vaccine coverage levels from infancy throughout childhood by successful implementation of the infant and childhood immunization program,” the authors said.
If parents decide to stop vaccinating their children, however, the results can be fatal.
“These vaccines work, and they improve the health of our children and our population, and we should be very grateful for that,” said Dr. Marian Michaels, an infectious disease specialist at Children’s Hospital of Pittsburgh. “But we should not become complacent. These diseases aren’t eradicated everywhere, and the world is so globally small now that these infections could come back if we don’t maintain high immunization rates.”
Scientists in Oklahoma are hopeful about Alzheimer’s vaccine
OKLAHOMA CITY Oklahoma City scientists have developed a vaccine that could restrain or even thwart Alzheimer’s Disease, according to The Oklahoman online.
The vaccine, designed to fight dementia in the brain via the human immune system, could reach human clinical trials in three to four years, according to officials at the Oklahoma Medical Research Foundation.
“These results are extremely exciting,” said Jordan Tang, OMRF researcher who led the laboratory study that resulted in the vaccine. “They certainly show that this vaccination approach warrants additional investigation as a therapy for Alzheimer’s disease.”
The illness, a fatal, memory-robbing disease, affects several million Americans, including 70,000 Oklahomans. November is National Alzheimer’s Disease Awareness Month.
Results of OMRF’s vaccine research appeared in the Oct. 21 edition of The Journal of the Federation of American Societies for Experimental Biology. “This is the first time this type of Alzheimer’s vaccine has been produced anywhere. Other types of vaccines have been tried, but have failed,” OMRF spokesman Adam Cohen said.
Tang had pointed out that while the vaccine should be an addition to developments to cure the disease, rather than a substitution, the vaccine is still in its critical stages.
Back 2002, the pharmaceutical company Elan halted trials of a different vaccine after 15 patients suffered swelling of the central nervous system. OMRF president, Dr. Stephen Prescott, said he’s hopeful Tang’s work will avoid the pitfalls that weighed down Elan’s vaccine. “This vaccination stimulates the immune system more gently than previous Alzheimer’s vaccines, so we are optimistic about its prospects going forward,” he said.
Avastin study on pancreatic cancer effects mixed results
ZURICH , Switzerland A new late-stage study of Roche Holding’s Avastin, and its effectiveness to slow down or avert pancreatic cancer in patients, had mixed results, the company said Tuesday.
The Swiss drugmaker said that although the addition of its drug to a Tarceva-chemotherapy combination failed to prolong the lives of patients with advanced pancreatic cancer, certain subjects did have some benefits when using Avastin.
Roche said that the study, which included 607 patients, showed that adding Avastin prolonged the time patients lived without their cancer worsening, as well as adding safety benefits.
An earlier trial, the company said, utilizing the same experiment, concluded that the addition of Avastin had shown no benefit in the treatment of pancreatic cancer.
Roche, which sponsored the study known as AVITA, plans to further analyze the data to determine the extent of the benefit of adding Avastin to the Tarceva-chemotherapy combination. The new details that surfaced from the study will not be published, the drugmaker said.
Pancreatic cancer, deemed the most difficult form of cancer to treat, is frequently resistant to chemotherapy and radiotherapy, and tends to spread quickly to other parts of the body. It leads to the shortest life expectancy of any major tumor.
Avastin, which hinders the growth of tumors by restraining their blood supply, was jointly developed with Genentech, a U.S. biotechnology company (majority-owned by Roche), and is seen as one of Roche’s most important drugs.
Financial experts believe Avastin will eventually become Roche’s best-selling drug, according to Dow Jones, since the drug is expected to be approved to treat several types of cancers.
Avastin was first approved in the U.S. in 2004 for the treatment of advanced colorectal cancer, and was approved for the treatment of lung cancer one year later. It is currently awaiting sanction for use in breast cancer. In Europe, it won approval for the treatment of advanced breast cancer and lung cancer earlier this year.